Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Thrive Health and Wellness, LLC dba Thrive Health Solutions

Has Thrive Health Solutions received an FDA warning letter? Yes. FDA issued a warning letter dated February 9, 2026 concerning products containing tirzepatide.

Letter facts

Letter date
February 9, 2026 (2026-02-09)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Compounding Pharmacy
Products named
NAD+ 50 mg/mLMEGALean (Tirzepatide/Cyanocobalamin) Injections 10mg/20mg/mLrepackaged sterile drug products
Violation categories
Unapproved new drugMisbrandingCGMP / insanitary conditions

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

CGMP / insanitary conditions

FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.

Factual Violation Summary

FDA says sterile drugs repackaged under insanitary conditions: aseptic filling outside ISO 5, no media fills, carpeted facility, non-sterile gloves/wipes, no sporicidal agent; products also unapproved and misbranded.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • Adulterated drug products (insanitary conditions)
  • Unapproved new drug products
  • Misbranded drug products

More letters about Tirzepatide

Recent FDA warning letters concerning Tirzepatide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.